BioSpace News Archive

Business

Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023

Accuray Incorporated will report financial results for the third quarter of fiscal year 2023, ended March 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 26, 2023.

April 13, 2023
·
1 min read
Biotech Beach

Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

Oncternal Therapeutics, Inc. announced that two key industry opinion leaders and management will participate in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m.

April 13, 2023
·
3 min read
Biotech Beach

AVITA Medical Announces Update to Automation Device

AVITA Medical, Inc. announced that its automated device, RECELL GO, maintains the Food and Drug Administration Breakthrough Device designation for the treatment of acute wounds.

April 13, 2023
·
3 min read
Deals

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

CytoMed Therapeutics Limited (“CytoMed” or the “Company”) today announced the pricing of its initial public offering of its 2,412,369 ordinary shares at a price of US$4.00 per share, for gross proceeds of US$9,649,476.00 before deducting underwriting discounts, commissions and offering expenses.

April 13, 2023
·
3 min read
Policy

Alvotech Provides Regulatory Update on AVT02 Biologics License Application

Alvotech announced that the U.S. Food and Drug Administration has issued a complete response letter for Alvotech’s Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.

April 13, 2023
·
8 min read
JEOL: Release of Cryogen Reclamation System

JEOL Ltd. announces launch of a new Cryogen Reclamation System for Nuclear Magnetic Resonance on April 14, 2023.

April 13, 2023
·
2 min read
Pharm Country

Complete Response Letter Received for AVT02 Biologics License Application

Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has issued a complete response letter to its partner Alvotech for the Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira®.

April 13, 2023
·
3 min read